Isolated rat hearts were subjected to 30-min coronary artery occlusion followed by 120-min reperfusion. The hearts (n=8–12) were perfused with Krebs-Henseleit solution enriched with L-carnitine (0.5, 2.5 and 5 mM) for 10 min before and after ischemia or reperfusion and for the whole period of ischemia and reperfusion. Two-hour perfusion with L-carnitine during ischemia/reperfusion markedly (p<0.05) and dose-dependently decreased the incidence of ventricular tachycardia (VT, maximum 65%). The incidence of reperfusion ventricular fibrillation (VF) also decreased from 63% (control) to 17% in hearts perfused with 5 mM L-carnitine, as reflected by a significant (p<0.05) decline in VF duration from 218±99 sec in control to 19±19 sec. Perfusion of etomoxir (palmitoylcarnitinetransferase-1 inhibitor) along with L-carnitine reversed the antiarrhythmogenic action of L-carnitine. Interestingly, short time preischemic administration of L-carnitine produced a concentration-dependent arrhythmogenic effects on both ischemia and reperfusion-induced arrhythmias. These results show that L-carnitine produced a protective effect against reperfusion arrhythmias only when it was perfused for the whole period of the experiment. This protective action was reversed by concomitant use of etomoxir, suggesting that the efficacy of L-carnitine is due to its mitochondrial action but cannot be solely attributed to increased fatty acid oxidation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. P. Almeida, S. F. Cortes, A. J. Ferreira, and V. S. Lemos, Life Sci., 70, No. 10, 1121–1128 (2002).
J. Cui, D. K. Das, A. Bertelli, and A. Tosaki, Mol. Cell. Biochem., 254, Nos. 1–2, 227–234 (2003).
R. Ferrari, E. Merli, G. Cicchitelli et al., Ann. N. Y. Acad. Sci., 1033, 79–91 (2004).
D. A. Ford, Prog., Lipid Res., 41, No. 1, 6–26 (2002).
D. J. Hausenloy, M. R. Duchen, and D. M. Yellon, Cardiovasc. Res., 60, No. 3, 617–625 (2003).
R. Lango, R. T. Smolenski, M. Narkiewicz et al., Ibid., 51, No. 1, 21–29.
G. D. Lopaschuk, Am. Heart J., 139, No. 2, S115–S119 (2000).
G. D. Lopaschuk, Am. J. Cardiol., 82, No. 5A, 14K–17K (1998).
G. D. Lopaschuk, M. A. Spafford, N. J. Davies, and S. R. Wall, Circ. Res., 66, No. 2, 546–553 (1990).
P. Rizzon, G. Biasco, M. Di Biase, et al., Eur. Heart J., 10, No. 6, 502–508 (1989).
A. Tosaki, D. T. Engelman, R. M. Engelman, and D. K. Das, Cardiovasc. Res., 31, No. 4, 526–536 (1996).
N. A. Trueblood, R. Ramasamy, L. F. Wang, and S. Schaefer, Am. J. Physiol., Heart and Cir. Physiol., 279, No. 2, H764–771 (2000).
M. J. Walker, M. J. Curtis, D. J. Hearse, et al., Cardiovasc. Res., 22, No. 7, 447–455 (1988).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 146, No. 8, pp. 175–178, August, 2008
Rights and permissions
About this article
Cite this article
Najafi, M., Garjani, A., Maleki, N. et al. Antiarrhythmic and arrhythmogenic effects of L-carnitine in ischemia and reperfusion. Bull Exp Biol Med 146, 210–213 (2008). https://doi.org/10.1007/s10517-008-0249-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-008-0249-5